Aegerion To Pay $40M To End Host Of Juxtapid Claims
By Rachel Graf · September 22, 2017, 5:20 PM EDT
Massachusetts-based biopharmaceutical company Aegerion Pharmaceuticals Inc. agreed Friday to pay about $40 million to end criminal and civil allegations by the U.S. Department of Justice and fraud charges brought by the...
To view the full article, register now.